A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis Having Chronic Inflammation
Latest Information Update: 07 Mar 2022
At a glance
- Drugs KIO 101 (Primary)
- Indications Anterior uveitis; Intermediate uveitis; Panuveitis; Posterior uveitis; Uveitis
- Focus Adverse reactions
- Sponsors Panoptes Pharma
- 19 Sep 2019 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
- 19 Sep 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Nov 2019.
- 19 Sep 2019 Status changed from recruiting to active, no longer recruiting.